Abstract:Objective To explore hypermethylation of RARβ2, GSTP1 and DAPK gene in prostate cancer tissues, and to explore its correlation with clinicopathological features of prostate cancer and its diagnostic value. Methods Hypermethylation of RARe2, GSTP1 and DAPK gene was detected by nested methylation-specific PCR (NMSP) in 57 prostate cancer (PCa) tissues and 35 benign prostate hyperplasia (BPH) tissues. The correlation between hypermethylation and clinicopathological features of prostate cancer and its diagnostic value were analyzed. Results The hypermethylation frequencies of RARβ2, GSTP1 and DAPK gene in PCa were significantly higher than those in BPH (RARβ2: 52.6% vs. 0% GSTP1: 61.4% vs. 2.9%;DAPK: 43.9% vs. 8.6%;all P<0.01). The methylation rate of RARβ2 gene was directly correlated with distinct Gleason scores and clinical stage (4～7 score vs. 8～10 score: 34.8% vs. 64.7%;stage B, C vs. stage D: 37.0% vs. 66.7%;x2=4.927 and 5.004, P=0.026 and 0.025). The methylation rate of GSTP1 gene was significantly different in patients with different Gleason scores (4～7 score vs. 8～10 score: 43.5% vs. 73.5%;x2 =11.530, P=0.001), but had no difference in patients with distinct clinical stage (stage B, C vs. stage D: 51.9% vs. 70.0%;x2=1.975, P=0.16) . There was no difference in DAPK gene methylation rate among patients with different Gleason scores and distinct clinical stage (4 ～7 score vs. 8～10 score: 39.1% vs. 50.0%;stage B, C vs. stage D: 33.3% vs. 53.3%;x2= 1.290 and 2.309, both P～0.05). GSTP1 gene showed the highest sensitivity of 61.4% (35/57)with specificity of 97.1%(34/35), while RARβ2 gene had the highest specificity of 100% (35/35) with the sensitivity of 52.6% (30/57). The sensitivity and specificity of DAPK gene were 43.9% and 91.4% (25/57 and 32/35), respeetively. When the hypermethylation of RARβ2, GSTP1 and DAPK gene were detected together, the diagnostic sensitivity was increased, but the specificity was decreased. Conclusions The aberrant methylation of RARβ2, GSTP1 and DAPK gene is correlated with tumorigenesis and progression of prostate cancer, which may be used as an effective diagnostic marker for prostate cancer.

Detection of Promoter Hypermethlation of DAPK Gene in Sera from Non-small Cell Lung Cancer Patients by Modified MSP

Detection of aberrant methylation of RARβ2, GSTP1 and DAPK gene in prostate cancer and its clinical significance

Analysis of Promoter Hypermethylation of Death-Asscciated Protein Kinase Gene in Blood from Non-Small Cell Lung Cancer Patients

Hypermethylation of GSTP1 and DAPK gene in prostate cancer

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

Analysis of Promoter Hypermethylation of P16 Gene in Sera from Non-Small Cell Lung Cancer Patients

Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer patients

Promoter Hypermethylation of P16 Gene and DAPK Gene in Sera from Hepatocellular Carcinoma (HCC) Patients

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.

Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients

Digital Loop-Mediated Isothermal Amplification-Based Absolute Methylation Quantification Revealed Hypermethylated DAPK1 in Cervical Cancer Patients

Detection of Methylation of DAPK Gene Promoter in Human Bone Marrow Mesenchymal Stem Cells and Its Transformed Mutant F6 Cells

A Panel of Promoter Methylation Markers for Invasive and Noninvasive Early Detection of NSCLC Using a Quantum Dots-Based FRET Approach.

Identification of a Panel of Candidate Epigenetic Biomarkers for Non-Small Cell Lung Cancer

Analysis of Methylation Status of RASSF1A promoter Region and Transcription Level of Downstream Genes in Non-Small Cell Lung Cancer

Methylation Status of DLEC1 Promoter in Colorectal Cancer Patients and Its Clinical Relevance

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis

Multiplex Digital Methylation‐Specific PCR for Noninvasive Screening of Lung Cancer